{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:36:46Z","timestamp":1793331406628,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS177"],"award-info":[{"award-number":["DS177"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Multiple Myeloma (MM), a prevalent hematological malignancy, poses significant treatment challenges due to varied patient responses and toxicities to chemotherapy. This study investigates the predictive value of pretreatment serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), and vascular endothelial growth factor (VEGF) for chemotherapy-induced toxicities in newly diagnosed MM patients. We hypothesized that these cytokines, pivotal in the tumor microenvironment, might correlate with the incidence and severity of treatment-related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective observational study with 81 newly diagnosed MM patients, analyzing serum cytokine levels using the multiplex cytometric bead assay (CBA) flow cytometry method. The study used non-parametric and multivariate analysis to compare cytokine levels with treatment-induced toxicities, including lymphopenia, infections, polyneuropathy, and neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our findings revealed significant associations between cytokine levels and specific toxicities. IL-8 levels were lower in patients with lymphopenia (p=0.0454) and higher in patients with infections (p=0.0009) or polyneuropathy (p=0.0333). VEGF concentrations were notably lower in patients with neutropenia (p=0.0343). IL-8 demonstrated an 81% sensitivity (AUC=0.69; p=0.0015) in identifying infection risk. IL-8 was an independent predictor of lymphopenia (Odds Ratio [OR]=0.26; 95% Confidence Interval [CI]=0.07-0.78; p=0.0167) and infection (OR=4.76; 95% CI=0.07-0.62; p=0.0049). High VEGF levels correlated with a 4-fold increased risk of anemia (OR=4.13; p=0.0414).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pre-treatment concentrations of IL-8 and VEGF in serum can predict hematological complications, infections, and polyneuropathy in patients with newly diagnosed MM undergoing chemotherapy. They may serve as simple yet effective biomarkers for detecting infections, lymphopenia, neutropenia, and treatment-related polyneuropathy, aiding in the personalization of chemotherapy regimens and the mitigation of treatment-related risks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1377546","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T04:19:50Z","timestamp":1716437990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor"],"prefix":"10.3389","volume":"15","author":[{"given":"Micha\u0142","family":"Mielnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Podgajna-Mielnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Szudy-Szczyrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Homa-Mlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Mlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Gor\u0105cy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20136736(21)01602\u20130","article-title":"A new era of novel immunotherapies for multiple myeloma","volume":"398","author":"Kazandjian","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.2020\u20130141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/LEU.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1178224219868235","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20132045(14)70442\u20135","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/S41408\u2013022-00645\u20131","article-title":"Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update","volume":"12","author":"Bazarbachi","year":"2022","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/S12325\u2013022-02083\u20138","article-title":"Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: A systematic literature review and network meta-analysis","volume":"39","author":"Facon","year":"2022","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.6004\/JNCCN.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20132045(20)30756\u20137","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/BLOOD-2020\u2013134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2045724","article-title":"Promising therapeutic approaches for relapsed\/refractory multiple myeloma","volume":"27","author":"Ni","year":"2022","journal-title":"Hematology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.750507","article-title":"Mechanisms of chemotherapy-induced neurotoxicity","volume":"13","author":"Was","year":"2022","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/J.MAYOCP.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: guidelines from the mayo stratification for myeloma and risk-adapted therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/J.CARDFAIL.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1733968","article-title":"The safety of current and emerging therapies for multiple myeloma","volume":"19","author":"Nadeem","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.844779","article-title":"Beyond clinical trials in patients with multiple myeloma: A critical review of real-world results","volume":"12","author":"Bertamini","year":"2022","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/J.EXPHEM.2006.06.017","article-title":"Chemokines in multiple myeloma","volume":"34","author":"Aggarwal","year":"2006","journal-title":"Exp Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/J.CYTO.2020.155358","article-title":"Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels","volume":"138","author":"Gu","year":"2021","journal-title":"Cytokine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/J.CYTO.2020.155271","article-title":"Cytokine profile in multiple myeloma","volume":"136","author":"Jasrotia","year":"2020","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20130432.CCR-07\u20134843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/00062752\u2013200005000\u201300009","article-title":"Role of interleukin-8 in neutrophil signaling","volume":"7","author":"Zeilhofer","year":"2000","journal-title":"Curr Opin Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1755\u20137682-3\u201311","article-title":"Interleukin 8 (IL-8)-a universal biomarker","volume":"3","author":"Shahzad","year":"2010","journal-title":"Int Arch Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V98.1.187","article-title":"Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: Implications for multiple myeloma progression","volume":"98","author":"Shapiro","year":"2001","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.40.23282","article-title":"High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4","volume":"270","author":"Daly","year":"1995","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.184.5.1825","article-title":"Involvement of interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: Evidence from mice lacking the murine IL-8 receptor homologue","volume":"184","author":"Broxmeyer","year":"1996","journal-title":"J Exp Med"},{"key":"B29","first-page":"76","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"1","author":"Ria","year":"2011","journal-title":"Am J Blood Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1055\/S-0040\u20131714933\/ID\/JR_17","article-title":"Evaluation of angiogenesis in multiple myeloma by VEGF immunoexpression and microvessel density","volume":"12","author":"Palta","year":"2020","journal-title":"J Lab Physicians"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13194787","article-title":"Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma","volume":"13","author":"Ackley","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.BJC.6600833","article-title":"Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3","volume":"88","author":"Vande Broek","year":"2003","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/BLOOD.V96.1.34","article-title":"Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression","volume":"96","author":"Salcedo","year":"2000","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0082453","article-title":"Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES11113012","article-title":"The clinical relevance of selected cytokines in newly diagnosed multiple myeloma patients","volume":"11","author":"Mielnik","year":"2023","journal-title":"Biomedicines"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/1097\u20130142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.LEU.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/AJH.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk-stratification and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/JIR.2011.0065","article-title":"Cytokines in autoimmunity: role in induction, regulation, and treatment","volume":"31","author":"Moudgil","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/INTIMM\/DXAA078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"B43","unstructured":"Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE)2017"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLIM.2003.11.017","article-title":"Cytometric bead array: a multiplexed assay platform with applications in various areas of biology","volume":"110","author":"Morgan","year":"2004","journal-title":"Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/CYTO.A.22287","article-title":"Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology","volume":"83","author":"Bongoni","year":"2013","journal-title":"Cytometry Part A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMETH.2005.11.010","article-title":"Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA","volume":"38","author":"Elshal","year":"2006","journal-title":"Methods"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/CYTO.A.23170","article-title":"Development of a bead-based multiplexed assay for simultaneous quantification of five bovine cytokines by flow cytometry","volume":"91","author":"Rodrigues","year":"2017","journal-title":"Cytometry Part A"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/S12253\u2013013-9614\u20134","article-title":"The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple","volume":"19","author":"Pappa","year":"2013","journal-title":"Pathol Oncol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005\u201304-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/J.CYTO.2007.02.007","article-title":"Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis","volume":"36","author":"Livaditi","year":"2006","journal-title":"Cytokine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000000294","article-title":"Predictive value of IL-8 for sepsis and severe infections after burn injury: A clinical study","volume":"43","author":"Kraft","year":"2015","journal-title":"Shock"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/165974","article-title":"Cytokines in sepsis: potent immunoregulators and potential therapeutic targets\u2013an updated view","volume":"2013","author":"Schulte","year":"2013","journal-title":"Mediators Inflammation"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/J.CECA.2005.01.019","article-title":"Interleukin-8 primes oxidative burst in neutrophil-like HL-60 through changes in cytosolic calcium","volume":"37","author":"Br\u00e9chard","year":"2005","journal-title":"Cell Calcium"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/J.FEBSLET.2010.11.031","article-title":"IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3)","volume":"585","author":"Henkels","year":"2011","journal-title":"FEBS Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.19746\/J.CNKI.ISSN.1009\u20132137.2021.01.046","article-title":"[Clinical significance of interleukin-2 receptor, interleukin-8 expression levels in the diagnosis of infection in patients with hematological Malignancies]","volume":"29","author":"Wu","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.17422","article-title":"Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study","volume":"193","author":"van de Geer","year":"2021","journal-title":"Br J Haematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/S15010\u2013005-5068\u20132","article-title":"Interleukin-8 serum levels at fever onset in patients with neutropenia predict early medical complications","volume":"33","author":"Engel","year":"2005","journal-title":"Infection"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.20452\/PAMW.15980","article-title":"Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a \u201creal-world\u201d study: Experiences of the Polish Myeloma Group","volume":"131","author":"Charli\u0144ski","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000000347","article-title":"Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsis","volume":"43","author":"Chung","year":"2015","journal-title":"Shock"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.20367","article-title":"Bone marrow and blood plasma levels of IL-8 in aplastic anemia and their relationship with disease severity","volume":"79","author":"Tripathy","year":"2005","journal-title":"Am J Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000724","article-title":"Interleukin-6 and interleukin-8 levels correlate with the severity of aplastic anemia in children","volume":"39","author":"Gupta","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/S00066\u2013002-0925\u20138","article-title":"Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF)","volume":"178","author":"Dunst","year":"2002","journal-title":"Strahlenther Onkol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/BF02742340","article-title":"Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis","volume":"175","author":"Dunst","year":"1999","journal-title":"Strahlenther Onkol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.5603\/AHP.2021.0071","article-title":"Peripheral neuropathy in patients with multiple myeloma: molecular effects of bortezomib","volume":"52","author":"\u0141uczkowska","year":"2021","journal-title":"Acta Haematol Pol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2003.02323.x","article-title":"Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration","volume":"134","author":"Hillyer","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/S41598\u2013017-07230\u20138","article-title":"Analysis of inflammatory cytokine and TLR expression levels in Type 2 Diabetes with complications","volume":"7","author":"Gupta","year":"2017","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V87.4.1458.BLOODJOURNAL8741458","article-title":"Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome","author":"Gherardi","year":"1996","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRITREVONC.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/J.1365\u20132354.2007.00797.X","article-title":"Impact of neutropenia on delivering planned chemotherapy for solid tumours","volume":"17","author":"Khan","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDW325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687150","article-title":"Association of time to antibiotics and clinical outcomes in adult hematologic Malignancy patients with febrile neutropenia","volume":"23","author":"Butts","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7870590","article-title":"Plasma levels of monocyte chemotactic protein-1 are associated with clinical features and angiogenesis in patients with multiple myeloma","volume":"2016","author":"Valkovi\u0107","year":"2016","journal-title":"BioMed Res Int"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/BLOOD-2011\u201302-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140\u20136736(19)31240\u20131","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.12946","article-title":"Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis","volume":"166","author":"Leiba","year":"2014","journal-title":"Br J Haematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V90.7.2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12\u2013associated toxicity and interferon-\u03b3 Production","volume":"90","author":"Moreau","year":"1997","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/TOXSCI\/KFQ134","article-title":"Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use","volume":"117","author":"Tarrant","year":"2010","journal-title":"Toxicological Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1377546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T04:19:57Z","timestamp":1716437997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1377546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2024.1377546"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1377546","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"article-number":"1377546"}}